文献速递白血病

基于微小RNA表达模型提示儿童急性髓系白血病无事件生存

MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia.
PubMed 文献 · J Clin Oncol · 2017-10-25

该研究对1362份儿童急性髓系白血病样本进行微小RNA测序,用惩罚性lasso Cox回归识别出36个与无事件生存相关的微小RNA并构建AMLmiR36风险分类方案,在878例来自两项临床试验的患者中独立验证,该方案可识别治疗失败高风险(HR 2.830,P≤.001)和低风险(HR 0.323,P≤.001)患者,且独立于常规核型或突变状态。

要点

  • 基于36个微小RNA的AMLmiR36风险分类可识别儿童AML治疗失败高风险(HR 2.830)和低风险(HR 0.323)患者。
  • AMLmiR36的预测性能独立于常规核型或突变状态,并在AAML0531和AAML1031共878例患者中独立验证。
  • miR-106a-363在复发和难治样本中高表达,miR-106a-5p的候选靶基因参与氧化磷酸化。

核心结论

  • 研究设计并验证了基于微小RNA的风险分类方案AMLmiR36,用于儿童急性髓系白血病的结局预测。
  • 作者假设miR-106a的丰富表达可能通过调节参与氧化磷酸化的基因而增加治疗抵抗。

研究设计与样本

  • 对1362份样本进行微小RNA测序:1303份初诊样本、22份难治样本和37份复发样本。
  • 对164份匹配样本(127份初诊和37份复发)进行RNA测序分析。
  • 使用惩罚性lasso Cox比例风险回归识别与无事件生存相关的微小RNA。
  • 使用来自两项不同临床试验(AAML0531和AAML1031)的878例患者独立评估AMLmiR36性能。

主要发现

  • 识别出36个微小RNA,其诊断时表达水平与无事件生存高度相关。
  • AMLmiR36识别治疗失败高风险患者(风险比2.830;P≤.001)和低风险患者(风险比0.323;P≤.001),独立于常规核型或突变状态。
  • miR-106a-363在复发和难治样本中丰富表达,miR-106a-5p的若干候选靶基因参与氧化磷酸化,该过程在治疗抵抗的白血病细胞中被抑制。

关键数值与推荐

  • 高风险组风险比2.830(P≤.001),低风险组风险比0.323(P≤.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Children with acute myeloid leukemia (AML) whose disease is refractory to standard induction chemotherapy therapy or who experience relapse after initial response have dismal outcomes. We sought to comprehensively profile pediatric AML microRNA (miRNA) samples to identify dysregulated genes and assess the utility of miRNAs for improved outcome prediction. Patients and Methods To identify miRNA biomarkers that are associated with treatment failure, we performed a comprehensive sequence-based characterization of the pediatric AML miRNA landscape. miRNA sequencing was performed on 1,362 samples-1,303 primary, 22 refractory, and 37 relapse samples. One hundred sixty-four matched samples-127 primary and 37 relapse samples-were analyzed by using RNA sequencing. Results By using penalized lasso Cox proportional hazards regression, we identified 36 miRNAs the expression levels at diagnosis of which were highly associated with event-free survival. Combined expression of the 36 miRNAs was used to create a novel miRNA-based risk classification scheme (AMLmiR36). This new miRNA-based risk classifier identifies those patients who are at high risk (hazard ratio, 2.830; P ≤ .001) or low risk (hazard ratio, 0.323; P ≤ .001) of experiencing treatment failure, independent of conventional karyotype or mutation status. The performance of AMLmiR36 was independently assessed by using 878 patients from two different clinical trials (AAML0531 and AAML1031). Our analysis also revealed that miR-106a-363 was abundantly expressed in relapse and refractory samples, and several candidate targets of miR-106a-5p were involved in oxidative phosphorylation, a process that is suppressed in treatment-resistant leukemic cells. Conclusion To assess the utility of miRNAs for outcome prediction in patients with pediatric AML, we designed and validated a miRNA-based risk classification scheme. We also hypothesized that the abundant expression of miR-106a could increase treatment resistance via modulation of genes that are involved in oxidative phosphorylation.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lim EL, Trinh DL, Ries RE, et al. MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia. J Clin Oncol. 2017. PMID: 29068783. doi:10.1200/JCO.2017.74.7451

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。